Post sponsored by NewzEngine.com

Source: Pharmac

PHARMAC is seeking feedback from pharmaceutical suppliers and interested parties on:

  • A proposal to tender certain pharmaceuticals for principal supply;

  • The implications of awarding Principal Supply Status; and

  • Commercial proposals as an alternative to tendering.

PHARMAC welcomes all feedback on the draft 2020/21 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal.

Download a PDF version of this consultation [PDF, 210 KB]

Feedback should be submitted by the following dates; late feedback may not be considered:

Alternative commercial proposal responses due by:
4 pm (New Zealand Time), Monday 24 August 2020

All other consultation responses due by:
4 pm (New Zealand Time), Monday 31 August 2020

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: tender@pharmac.govt.nz

Letter: Tender Analysts
PHARMAC
PO Box 10-254
Wellington 6143

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposed 2020/21 Tender

In general, the proposed 2020/21 Tender process would be similar to the 2019/20 Tender. However, the 2020/21 Tender would result in awarding Principal Supply Status (PSS) (previously Sole Supply Status and/or Hospital Supply Status).

In essence, this change would mean that a Discretionary Variance provision (renamed Alternative Brand Allowance) would apply across both the community and hospital markets, rather than just the hospital market.

Principal Supply Status was subject to an initial consultation in July 2020. In addition to Alternative Commercial Proposals (discussed below), we seek comments on all sections of the draft 2020/21 Tender, in particular on:

  • The proposed changes in the draft 2020/21 Tender;
  • An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2020/21 Tender, that you consider should be tendered, and the reasons for that view. If you wish, you may provide a non-binding confidential indication of the price or price range that you might be able to offer for a line item or group of line items you wish to have tendered;
  • An indication of any pharmaceuticals, whether or not they are included in Schedule Two of the draft 2020/21 Tender, that you consider would be inappropriate to tender, and the reasons for that view, including any contractual constraints or patent protection that could restrict PHARMAC from awarding a tender on a particular pharmaceutical;
  • Your views on whether any product included in Schedule Two might have more than 5% of patients needing to access an alternative brand;
  • Feedback on any unresolved Tender Bid(s) from previous tenders that you consider should remain open for acceptance. Please note that some currently unresolved Tender Bids may be resolved prior to the consultation deadline and the final 2020/21 Tender being issued.

Draft Invitation to Tender

We are seeking feedback on the composition of the draft 2020/21 Tender. This is still under development and may change before it is taken to the Board (or its Delegate) for approval and subsequently issued. At this stage, but depending on the extent of any changes, PHARMAC does not intend to send out further drafts for consultation.

A complete copy of the draft 2020/21 Tender, including the proposed terms and conditions which successful tender bids would be subject to, is available on our website.

Download the draft 2020/21 Invitation to Tender [PDF, 597 KB]

The draft 2020/21 Tender comprises the following sections:

Schedule 1: Definitions and interpretation

Schedule 2: The list of pharmaceuticals proposed for tender* #

Download Schedule 2: Products to be tendered [XLSX, 54 KB]

Download Supplement to Schedule 2: Includes pharmacodes [XLSX, 39 KB]

Schedule 3: The tender process (for both hospital and community tender bids)

Schedule 4: Contract terms for Principal Supply Status for both community and hospital supply

Schedule 5: Additional contract terms for Principal Supply Status for community supply

Schedule 6: Additional contract terms for Principal Supply Status for hospital supply

Schedule 7: Additional special terms for particular pharmaceuticals

*The units provided in Schedule Two consist of market data for the year ended 30 June 2020. The figures included are indicative only and are provided on the basis set out in clause 1.3 of Schedule 2 of the draft 2020/21 Tender.

#The final list of products, which may change following consultation, would be released as part of the 2020/21 Tender, following Board (or its Delegate) approval. You may provide feedback on the inclusion of any additional pharmaceuticals after the 2020/21 Tender has been issued, and any such feedback would be considered by the Board (or its Delegate) before making a final decision on any product, provided that any feedback is given prior to the tender close date in late 2020.

Proposed inclusion of the following provisions in the 2020/21 Invitation to Tender

Principal Supply Status

As outlined in the “Proposal to modify PHARMAC’s approach to competitive procurement” consultation dated 10 July 2020, we are proposing that the 2020/21 Invitation to Tender replaces Sole Supply Status and Hospital Supply Status with Principal Supply Status.

The purpose of the change is to extend the DV provisions (renamed Alternative Brand Allowance) across both markets.

  • PHARMAC would have flexibility regarding if and how to fund alternative brands in the community:
    • In some cases, this could be through listing (or maintaining the listing of) other brands under Special Authority criteria, and in others it may be through our exceptional circumstances framework.
    • Regardless of the mechanism used, we are intending to develop and communicate clear clinical criteria for the funding of alternative brands.
  • Our preliminary view is that alternative brand funding might be needed in three different circumstances:
    • If a patient has experienced adverse clinical outcomes as a result of a brand change,
    • If a patient has unique clinical circumstances that would put them at heightened risk of adverse clinical outcomes, and wishes to avoid a brand change, or
    • If a patient’s circumstances mean that they require a temporary delay to the brand switch.
  • This may not be all the circumstances in which we need to consider funding of an alternative brand. We are interested in receiving feedback on what the criteria for those circumstances should be, and whether there are other circumstances that we need to consider as well.
  • We note that brand changes are generally well-tolerated, and so we do not expect to fund alternative brands for all products. However, by implementing this change across all products, we would be able to respond to issues as they arise.
    • We are interested in receiving feedback on which chemicals (or indications for a chemical) might have a particular need for funding of an alternative brand (and why). In addition, for those situations, whether you consider that clinical destabilisation can be objectively determined, and if so, how.
  • We expect that the Alternative Brand Allowance would, in DHB hospitals, operate much as DV limits have in the past. However, PHARMAC would have the ability to manage this more closely if needed, such as setting clinical criteria.
  • The tender relates to supply of the principal brand only. Any commercial arrangements for the supply of other brands would be managed separately and may (as in the case of DV purchases) be managed outside of a supply agreement.
  • The proposed Alternative Brand Allowance limit is not a cap on the number of patients who could access an alternative brand, nor is it a prediction of that need. It is, as in the case of the DV limit, a threshold (indicated by the “ABA Limit” in Schedule Two) over which PHARMAC/DHBs would compensate the principal supplier. However, we are interested to understand if you consider that there are any products that we are proposing to tender where more than 5% of patients might need access an alternative brand.

The new provisions resulting from this change are as follows:

1.6 Principal Supplier

(a) You shall have Principal Supply Status during the Principal Supply Period, which shall be subject to the Alternative Brand Allowance, where other supplier brands of the Pharmaceutical may be subsidised in the community and/or purchased by DHB Hospitals.

(b) The Alternative Brand Allowance referred to in paragraph (a) above is specified as a percentage of the Total Pharmaceutical Volume for the Pharmaceutical, that percentage being as set out in Schedule Two.

(c) You acknowledge and agree that any other supplier brands of the Pharmaceutical may be concurrently listed on the Pharmaceutical Schedule at any time during the First Transition Period, the Principal Supply Period and the Final Transition Period and your rights under this Agreement do not extend to an exclusive listing of the Pharmaceutical on the Pharmaceutical Schedule.

1.7 Exceptions to Principal Supply Status

(a) PHARMAC may, from time to time during the Principal Supply Period or the First Transition Period, amend the Alternative Brand Allowance for the Pharmaceutical after consultation with a relevant medical adviser (being either the Ministry of Health, PTAC or its sub-committees), provided that PHARMAC may only increase the Alternative Brand Allowance without your prior agreement if it has a direction to that effect from Medsafe or its successor, or a recommendation that it do so from PTAC or its sub-committees, based on a significant clinical issue.

(b) Subject to clause 1.8 of this Schedule, you acknowledge and agree that while you have Principal Supply Status:

(i) other supplier brands of the Pharmaceutical may be subsidised in the community and/or purchased by DHB Hospitals, subject to the Alternative Brand Allowance; and

(ii) without derogating from any other rights available to PHARMAC, the Funder or DHB Hospitals under this Agreement or otherwise, if you fail to supply the Pharmaceutical in accordance with this Agreement (other than for a reason that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) at any time during the Principal Supply Period, then the Alternative Brand Allowance shall not apply and other supplier brands of the Pharmaceutical may be subsidised in the community and/or purchased by DHB Hospitals without limitation during that period of non-supply and any calculation performed in accordance with clause 1.8 below shall exclude that period of non-supply.

1.8 Principal Supply Status Monitoring

(a) If you reasonably believe that the percentage usage of other supplier brands of the Pharmaceutical subsidised in the community and/or purchased by DHB Hospitals exceeds the Alternative Brand Allowance for a particular Pharmaceutical during the Principal Supply Period, you may at any date after a three (3) month period following the end of any Relevant Period, request that PHARMAC carry out calculations for that Relevant Period in accordance with the procedure set out in this clause 1.8, and PHARMAC may, in its discretion, agree to carry out such calculations, provided that if PHARMAC refuses to carry out such calculations, it will provide you with the reasons for refusing to do so. For the avoidance of doubt, where you have Principal Supply Status for both community and hospital supply of a Pharmaceutical, PHARMAC will carry out any calculations for those markets in combination, with a single, combined figure to be used for each of Total Pharmaceutical Volume and Total Brand Allowance Pharmaceuticals when carrying out the calculations below.

(b) Within 30 business days of PHARMAC accepting your request to carry out calculations in accordance with paragraph (a) above, PHARMAC shall carry out the following calculations for the Relevant Period in question:

(i) (Total Brand Allowance Pharmaceuticals / Total Pharmaceutical Volume) x 100 = Brand Allowance Indicator;

(ii) Brand Allowance Indicator – Alternative Brand Allowance = Brand Differential

(c) In the event the Brand Differential is a number greater than zero i.e. a positive amount, PHARMAC shall carry out the following calculations for the Relevant Period in question:

(i) Total Pharmaceutical Volume / 100 = Volume Multiplier;

(ii) Volume Multiplier x Brand Differential = Eligible Volume;

(iii) (Eligible Volume x Unit Price and/or Unit Subsidy) / 2 = Brand Compensation

(d) PHARMAC will notify you in writing of any Brand Compensation payable in accordance with paragraph (c) above and will provide you with the details of the relevant party or parties to be invoiced, for example the relevant DHB(s). Following such notification to you from PHARMAC, you may invoice the relevant party or parties for the Brand Compensation.

(e) PHARMAC’s calculation for the purposes of this clause 1.8, shall not be subject to audit by you and you acknowledge and agree that the data extracted from the records used by PHARMAC are the best data and those records are the best records, for the purposes of carrying out the calculations.

New definitions associated with the proposed definitions have also been added. Provisions regarding DV Pharmaceuticals, DV Limit and DV Limit Compliance have been removed from the tender document.

Additional Special Terms

1. Somatropin

You shall provide the following resources and related products at no cost for the Pharmaceutical somatropin:

  • The provision of education, training and support Resources to endocrinologists, paediatric endocrinologists, pharmacies and patients in respect of the use of somatropin.
  • The Resources shall be provided to all endocrinologists, paediatric endocrinologists, pharmacies and patients in New Zealand or upon request by any relevant party.
  • The Resources shall be provided to patients when their prescription is filled and directly to all endocrinologists, paediatric endocrinologists and pharmacies before the commencement of the Principal Supply Period.
  • The provision of Related Products for your proposed brand of somatropin for the benefit of patients, in respect of the use of somatropin. The Related Products shall be delivered to the nominated delivery address of the prescribed patient.

For the purposes of this clause:

“Resources” shall include but not be limited to the:

  • provision of patient training and medical education and support for endocrinologists, paediatric endocrinologists and pharmacies on the use of somatropin devices, including a requirement for clinical educators to talk specifically with patients and for an 0800 number to be available for patients to contact with any further queries;
  • provision of training materials (DVDs, pamphlets, leaflets, brochures) to new patients; and
  • provision of presentations and/or demonstrations on the use of somatropin devices to patients and/or healthcare professionals.

“Related Products”, which shall be inclusive of the replacement of any defective Related Product, shall include but not be limited to devices, needles, needle clippers, sharps bins, and other products which are required for the safe treatment of your brand of somatropin.

Key Dates and Timeframes for the 2020/21 Tender:

The timelines for the 2020/21 Tender are envisaged to be similar to the 2019/20 Tender; we propose to release the final 2020/21 Invitation to Tender in early November 2020 and consequently the closing date for tender submissions would be late December 2020. The proposed timeline is outlined in the following table: 

4 August 2020

Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft 2020/21 Tender.

24 August 2020

Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.

31 August 2020

Final date for all consultation to be received.

September 2020

PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC’s Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.

September 2020

Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.

September/October 2020

Consultation and decisions on Alternative Commercial Proposals.

Early November 2020

Issuing of the 2020/21 Tender.

17 December 2020

Invitation to Tender closes.

From end of January 2021

Announcements on Tender decisions will commence.

Date

Event

Unresolved Tender Bids

We intend to review any unresolved Tender Bids from the 2018/19 Tender and the 2019/20 Tender prior to issuing the 2020/21 Tender. The following Tender Bids remain unresolved: 

2018/19 Invitation to Tender 

Chemical Name

Line Item

Aciclovir

Eye oint 3%

Cefalexin monohydrate

Cap 500 mg

Cyclizine lactate

Inj 50 mg per ml, 1 ml

Levonorgestrel

0.75 mg – 1.5 mg

Loperamide hydrochloride [split market]

Tab 2 mg

Loratadine

Oral liq 1 mg per ml

Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride

Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet

Minocycline hydrochloride

Tab 50 mg

Sodium nitroprusside

Inj 50 mg

Spironolactone

Tab 25 mg

Spironolactone

Tab 100 mg

Tenoxicam

Inj 20 mg

Teriparatide

Inj 250 mcg per ml

Tigecycline

Inj 50 mg

Vitamin B complex (strong)

Tab

2019/20 Invitation to Tender 

Chemical Name

Line Item

Acetazolamide

Tab 250 mg

Amoxicillin clavulanate

Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml

Amoxicillin clavulanate

Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml

Brimonidine Tartrate with Timolol Maleate

Eye drops 0.2% with timolol maleate 0.5%

Bupivacaine hydrochloride

Inj 2.5 mg per ml, 20 ml ampoule

Carbimazole

Tab 5 mg

Carmellose sodium

Eye drops 1%

Clobazam

Liq

Clotrimazole

Crm 1%

Colistin Sulphomethate

Inj 150 mg

Condoms

Female, non-latex

Condoms

Male 55 mm – 58 mm, non-latex

Disulfiram

Tab 200 mg

Docetaxel

Inj 20 mg

Docetaxel

Inj 80 mg

Ephedrine

Inj 3 mg per ml, 10 ml prefilled syringe

Erlotinib hydrochloride

Tab 100 mg

Erlotinib hydrochloride

Tab 150 mg

Escitalopram

Tab 10 mg

Escitalopram

Tab 20 mg

Ethinyloestradiol with levonorgestrel

Tab 30 mcg with levonorgestrel 150 mcg

Ethinyloestradiol with levonorgestrel

Tab 20 mcg with levonorgestrel 100 mcg

Exemestane

Tab 25 mg

Febuxostat

Tab 80 mg

Febuxostat

Tab 120 mg

Fludrocortisone Acetate

Tab 100 mcg

Glucose [Dextrose]

Solution 15 g

Glyceryl trinitrate

Inj 5 mg per ml, 10 ml ampoule

Hydrocortisone

Powder

Insulin pen needles

29 g x 12.7 mm

Insulin pen needles

31 g x 8 mm

Insulin pen needles

31 g x 5 mm

Insulin pen needles

31 g x 6 mm

Insulin pen needles

32 g x 4 mm

Insulin syringes, disposable with attached needle

Syringe 0.3 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle

Syringe 0.5 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle

Syringe 1 ml with 29 g x 12.7 mm needle

Insulin syringes, disposable with attached needle

Syringe 0.3 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle

Syringe 0.5 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle

Syringe 1 ml with 31 g x 8 mm needle

Insulin syringes, disposable with attached needle

Syringe 0.3 ml with 29 g x 6 mm needle

Insulin syringes, disposable with attached needle

Syringe 0.5 ml with 29 g x 6 mm needle

Insulin syringes, disposable with attached needle

Syringe 1 ml with 29 g x 6 mm needle

Irbesartan

Tab/Cap 75 mg

Irbesartan

Tab/Cap 150 mg

Irbesartan

Tab/Cap 300 mg

Irbesartan with hydrochlorothiazide

Tab/Cap 150 mg with hydrochlorothiazide 12.5 mg

Irbesartan with hydrochlorothiazide

Tab/Cap 300 mg with hydrochlorothiazide 12.5 mg

Irbesartan with hydrochlorothiazide

Tab/Cap 300 mg with hydrochlorothiazide 25 mg

Ivabradine (current access)

Tab 5 mg

Ivabradine (current access)

Tab 7.5 mg

Ivabradine (widened access)

Tab 5 mg

Ivabradine (widened access)

Tab 7.5 mg

Lamivudine

Tab 300 mg

Latanoprost with timolol

Eye drops 0.005% with timolol 0.5%

Levosimendan

Inj 2.5 mg per ml, 5 ml

Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride

Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml syringe

Magnesium sulphate

Inj 2 mmol per ml, 5ml

Metaraminol tartrate

Inj 0.5 mg per ml, 10 ml

Metaraminol tartrate

Inj 0.5 mg per ml, 5 ml prefilled syringe

Metaraminol tartrate

Inj 0.5 mg per ml, 10 ml prefilled syringe

Morphine

Inj 10 mg per ml, 1 ml

Morphine

Inj 15 mg per ml, 1 ml

Morphine

Inj 30 mg per ml, 1 ml ampoule

Morphine

Inj 20 mg per ml

Morphine

Inj 50 mg per 5 ml

Morphine

Inj 100 mg per 5 ml

Mupirocin

Topical oint 2% (pack size 5 g or less)

Mupirocin

Intra-nasal oint 2%

Neostigmine metisulfate

Inj 2.5 mg per ml, 1 ml

Nitrofurantoin

Tab modified-release

Noradrenaline

Inj 0.1 mg per ml, 100 ml bag

Noradrenaline

Inj 0.1 mg per ml, 50 ml syringe

Noradrenaline

Inj 0.06 mg per ml, 50 ml syringe

Noradrenaline

Inj 0.12 mg per ml, 100 ml bag

Noradrenaline

Inj 0.16 mg per ml, 50 ml syringe

Noradrenaline

Inj 0.06 mg per ml, 50 ml vial

Noradrenaline

Inj 0.12 mg per ml, 50 ml vial

Octreotide (somatostatin analogue)

Inj 100 mcg per ml, 1 ml

Octreotide (somatostatin analogue)

Inj 50 mcg per ml, 1 ml

Octreotide (somatostatin analogue)

Inj 500 mcg per ml, 1 ml

Omeprazole

Cap 10 mg

Omeprazole

Cap 20 mg

Omeprazole

Cap 40 mg

Ondansetron hydrochloride

Inj 2 mg per ml, 2 ml

Ondansetron hydrochloride

Inj 2 mg per ml, 4 ml

Phenylephrine hydrochloride

Inj 10 mg per ml, 1 ml vial

Piperacillin with tazobactam

Inj 4 g with tazobactam 500 mg

Progesterone

Cap 100 mg

Rifaximin

Tab 200 mg – 550 mg

Rosuvastatin

Tab 5 mg

Rosuvastatin

Tab 10 mg

Rosuvastatin

Tab 20 mg

Rosuvastatin

Tab 40 mg

Silver Sulphadiazine

Crm 1% (pack size of 100 g or less)

Sodium alginate with sodium bicarbonate and calcium carbonate

Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml

Tacrolimus

Oint 0.1%

Tadalafil

Tab/Cap 5 mg

Tadalafil

Tab/Cap 10 mg

Tadalafil

Tab/Cap 20 mg

Tadalafil

Tab/Cap 2.5 mg

Talc

Dusting Powder BP

Teriflunomide (current access)

Tab 14 mg

Teriflunomide (widened access)

Tab 14 mg

Thiamine Hydrochloride

Tab 50 mg

Thiotepa

Inj 15 mg

Thiotepa

Inj 100 mg

Ticagrelor

Tab 90 mg

Tramadol hydrochloride

Oral soln 10 mg per ml

Travoprost

Eye drops 0.004%

Vitamins

Cap/tab (fat soluble vitamins A, D, E, K)

Water-based lubricant

Single use sachets, 4 ml/g or larger

Zinc

Paste (pack size 50 g or less)

Zinc

Crm (pack size greater than 50 g)

Zinc

Crm (pack size 50 g or less)

Zinc

Oint (pack size greater than 50 g)

Zinc

Oint (pack size 50 g or less)

Zinc and castor oil

Oint (pack size greater than 50 g)

Zinc and castor oil

Oint (pack size 50 g or less)

Should any unresolved Tender Bids be declined prior to the release of the 2020/21 Tender, PHARMAC would consider re-tendering those pharmaceuticals when the 2020/21 Tender is issued. Unresolved Tender Bids have not been included in the draft pharmaceutical list (Schedule Two). 

Products not currently listed in Section B of the Pharmaceutical Schedule 

The following products included in Schedule Two of the draft 2020/21 Tender are not currently listed in Section B of the Pharmaceutical Schedule: 

Chemical Name

Line Item

Alpha Tocopheryl Acetate

Oral liq 156 u per ml

Amiloride

Tab 5 mg

Amoxicillin clavulanate

Grans for oral liq amoxicillin 400 mg with

potassium clavulanate 57 mg per 5 ml

Aprepitant

Cap 80 mg

Aprepitant

Cap 125 mg

Aprepitant

Cap 165 mg

Baclofen

Oral liq

Budesonide

Rectal Enema 2 – 4 mg

Calcipotriol

Soln 50 mcg per ml (pack size 30 ml or greater)

Crotamiton

Lotn 10%

Efavirenz

Tab 50 mg

Etoricoxib

Tab 30 mg

Etoricoxib

Tab 60 mg

Etoricoxib

Tab 90 mg

Etoricoxib

Tab 120 mg

Fenofibrate

Cap/tab 48 mg

Fenofibrate

Cap/tab 145 mg

Fentanyl

Patches 6.25 mcg per hour

Ferrous Gluconate with Ascorbic Acid

Tab 170 mg with ascorbic acid 40 mg

Glyceryl Trinitrate

Tab sublingual 600 mcg

Heparin Sodium

Inj 1,000 iu per ml, 20 -35 ml

Hydrocortisone

Oint 1% (pack size 100 g or less)

Hydrocortisone

Oint 1% (pack size greater than 100 g)

Hydrocortisone

Oral liq

Hydrocortisone

Tab 1 mg

Hydrogen Peroxide

Crm 2%

Indomethacin

Inj

Indomethacin

Cap 25 – 50 mg

Indomethacin

Cap long-acting 75 mg

Indomethacin

Suppos 100 mg

Lanreotide

Inj 60 mg per 0.5 ml, 0.5 ml syringe

Lanreotide

Inj 90 mg per 0.5 ml, 0.5 ml syringe

Lanreotide

Inj 120 mg per 0.5 ml, 0.5 ml syringe

Liquid paraffin with white soft paraffin

Liquid paraffin 50% with white soft paraffin 50% ointment (pack size 100 g or less)

Lorazepam

Tab 0.5 mg

Metformin Hydrochloride

Cap/tab sustained-release 1 g

Metformin Hydrochloride

Cap/tab sustained-release 500 mg

Metformin Hydrochloride

Cap/tab immediate-release 1 g

Metronidazole

Gel 0.75%

Netupitant with Palonosetron

Cap netupitant 300 mg with palonosetron

500 mcg

Oil in Water Emulsion

Crm (pack size 100 g or less)

Omeprazole

Oral Suspension

Potassium citrate

Tab

Povidone Iodine

Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)

Povidone Iodine

Skin preparation, povidone iodine 10% with 70% alcohol (pack size greater than 100 ml)

Prednisolone

Rectal Enema 10 – 20%

Prednisolone

Rectal Foam 10 – 20%

Ramipril

Cap/tab 1.25 mg

Ramipril

Cap/tab 2.5 mg

Ramipril

Cap/tab 5 mg

Ramipril

Cap/tab 10 mg

Somatropin

Inj 0.05 mg per ml – 2.5 mg per ml, including overage

Somatropin

Inj 5.51 mg per ml – 9 mg per ml, including overage

Somatropin

Inj 0.05 mg per ml – 2.5 mg per ml, including overage

Sunitinib

Cap 37.5 mg

Terlipressin

Inj 0.2 mg per ml, 5 ml

Terlipressin

Inj 0.2 mg per ml, 10 ml

Testosterone

Transdermal patch 2.5 mg

 Electronic Tender (eTender) system

The 2020/21 Tender will be distributed via PHARMAC’s electronic tendering portal. The portal requires companies to register for a user account and details of how to register will be distributed prior to the release of the final 2020/21 Invitation to Tender. Please let us know if the contact details for the person responsible for submitting tender bids have changed for your company by sending an email to the Tender Analysts at tender@pharmac.govt.nz by 4 pm (New Zealand time), Friday 25 September 2020.

Alternative Commercial Proposals 

PHARMAC seeks any Alternative Commercial Proposals (ACPs) to tendering that you may wish to submit. An ACP may, for example, offer price reductions on one set of pharmaceuticals in return for PHARMAC agreeing to defer tendering on another group of pharmaceuticals for a period. 

Please note the following points apply to ACPs for both the community and DHB hospital markets: 

  • ACPs may include more than one line item and may include pharmaceuticals not listed in Schedule Two of the draft 2020/21 Tender;
  • ACPs may seek PHARMAC’s agreement to defer tendering or application of reference pricing for a period of time for any pharmaceutical, whether or not it is listed in Schedule Two of the draft 2020/21 Tender;
  • ACPs may not propose awarding Principal Supply Status in the community or DHB Hospitals;
  • PHARMAC reserves the right:
    • not to accept any ACPs; and/or
    • not to provide reasons for the acceptance or non-acceptance of any ACP; and/or
    • to enter into an agreement or arrangement that differs in a material respect from that envisaged in this letter.

ACPs are due by 4 pm (New Zealand Time), Monday 24 August 2020. PHARMAC may not consider any ACPs that are submitted after this date.

Usage data for ‘PCT only’ injectable products

 The table below contains ‘PCT only’ usage data for items included in the 2020/21 Tender. These volumes are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any tender item. 

Chemical and description

Total usage (mg)*

Azacitidine

370,423

Bendamustine

311,756

Bleomycin Sulphate

8,208,273,000**

Carboplatin

2,013,908

Cisplatin

137,868

Cyclophosphamide

6,134,574

Cytarabine

4,493,242

Doxorubicin

312,878

Epirubicin

82,099

Fluorouracil sodium

28,888,214

Idarubicin Hydrochloride

1,705

Irinotecan

955,641

Methotrexate

2,780,562

Oxaliplatin

783,467

Pemetrexed

1,061,695

*Usage in mg, for period between 1 January 2019 to 31 December 2019

** Usage shown in IU (international units)

Last updated: 4 August 2020

MIL OSI